

**Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab)
Recombinant Antibody
Catalog # APR10101****Specification**

Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) - Product Information

Application	FC, E, FTA
Primary Accession	P40199
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	144.76 KDa

Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) - Additional Information**Target/Specificity**
CEACAM6 / CD66c**Endotoxin**
< 0.001EU/ µg, determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.**Storage**
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) - Protein Information****Name** CEACAM6**Synonyms** NCA**Function**
Cell surface glycoprotein that plays a role in cell adhesion and tumor progression (PubMed: [10910050](http://www.uniprot.org/citations/10910050), PubMed: [11590190](http://www.uniprot.org/citations/11590190), PubMed: [1378450](http://www.uniprot.org/citations/1378450), PubMed: [14724575](http://www.uniprot.org/citations/14724575), PubMed: [16204051](http://www.uniprot.org/citations/16204051)).

href="http://www.uniprot.org/citations/2022629" target="_blank">2022629, PubMed:2803308, PubMed:8776764). Intercellular adhesion occurs in a calcium- and fibronectin-independent manner (PubMed:16204051, PubMed:2022629). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8 (PubMed:11590190, PubMed:16204051, PubMed:2022629, PubMed:2803308, PubMed:8776764). Heterophilic interaction with CEACAM8 occurs in activated neutrophils (PubMed:8776764). Plays a role in neutrophil adhesion to cytokine- activated endothelial cells (PubMed:1378450). Plays a role as an oncogene by promoting tumor progression; positively regulates cell migration, cell adhesion to endothelial cells and cell invasion (PubMed:16204051). Also involved in the metastatic cascade process by inducing gain resistance to anoikis of pancreatic adenocarcinoma and colorectal carcinoma cells (PubMed:10910050, PubMed:14724575).

Cellular Location

Cell membrane; Lipid-anchor, GPI-anchor. Apical cell membrane. Cell surface. Note=Localized to the apical glycocalyx surface.

Tissue Location

Expressed in neutrophils (PubMed:1378450). Expressed in columnar epithelial and goblet cells of the colon (PubMed:10436421). Expressed in numerous tumor cell lines (at protein level) (PubMed:16204051).


Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) - Images






Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) is more than 95.93%, determined by SEC-HPLC.



Immobilized human CEACAM6 His at 2 µg/mL can bind Anti-CEACAM6 / CD66c Reference Antibody (tinurilimab) $EC_{50}=0.005084$ µg/mL